drug development

Explore "drug development" with insightful episodes like "In spite of plummeting valuation, 23andMe still aims to pivot into biotech", "Snacksize 4: How to Measure Ageing", "Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]", "EP 155: AI's Edge in Pharma - Lowering Drug Failure Rates" and "What causes Alzheimer’s?" from podcasts like ""Marketplace Tech", "The Doctor's Kitchen Podcast", "Invest Like the Best with Patrick O'Shaughnessy", "Everyday AI Podcast – An AI and ChatGPT Podcast" and "Unexplainable"" and more!

Episodes (8)

In spite of plummeting valuation, 23andMe still aims to pivot into biotech

23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.

enFebruary 13, 2024

Snacksize 4: How to Measure Ageing

Todays Snacksize Doctor’s Kitchen podcast is all how we measure ageing. With all the interest in ageing and a burgeoning industry including drugs and supplements that claim to reverse your age, how do we know that they even work?

Andrew Steele on episode 118 gives us a wonderful summary of the ageing field, why epigenetic clocks are something to watch out for, as well as the hallmarks of ageing.

🥗 Join the newsletter and 7 day meal plan

📷 Follow on Instagram

🐦 Tweet me

We would love to get your feedback on the subject matter of these episodes - please do let me know on our social media pages (Instagram, Facebook & Twitter) what you think, and give us a 5* rating on your podcast player if you enjoyed today’s episode.

Hosted on Acast. See acast.com/privacy for more information.

The Doctor's Kitchen Podcast

enFebruary 02, 2024

Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]

My guest today is Alex Telford. Alex is the founder of Convoke, a software platform to help streamline drug development and commercialization. He also has been writing frequent blog posts on the biotech industry since 2019, keeping a pulse on the direction of innovation. He joined me today to talk about the history of the pharmaceutical industry and what’s becoming possible in medicine in the coming years. Alex helped break down the complexities of investing in new drug development, breakthroughs in gene therapy on the horizon, and the dance between timely progress and restrictive regulation. This industry has a lot to unpack, and he thoughtfully lays out the landscape. Please enjoy my conversation with Alex Telford. Listen to Founders Podcast For the full show notes, transcript, and links to mentioned content, check out the episode page here. ----- This episode is brought to you by Tegus, the modern research platform for leading investors. Stretch your research budget with flexible expert calls you can trust. At a fraction of the cost of traditional expert networks, Tegus customers pay only what an expert charges – with zero markups and no confusing call credits – netting an average 70% savings. Don’t want to conduct a full hour call? Tegus offers the ability to schedule 30-minutes, an offer you won’t find anywhere else. And they don’t stop there. With white-glove custom sourcing for every project and robust compliance measures, including a dedicated 50+ analyst team that vets every call transcript, Tegus ensures your privacy and protection. As the industry innovator for qualitative insights, Tegus helps you find the right experts you need at a quality and speed that can’t be matched. For a limited time, as a listener, you can trial Tegus for free by visiting tegus.co/patrick. ----- Invest Like the Best is a property of Colossus, LLC. For more episodes of Invest Like the Best, visit joincolossus.com/episodes. Past guests include Tobi Lutke, Kevin Systrom, Mike Krieger, John Collison, Kat Cole, Marc Andreessen, Matthew Ball, Bill Gurley, Anu Hariharan, Ben Thompson, and many more. Stay up to date on all our podcasts by signing up to Colossus Weekly, our quick dive every Sunday highlighting the top business and investing concepts from our podcasts and the best of what we read that week. Sign up here. Follow us on Twitter: @patrick_oshag | @JoinColossus Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Show Notes: (00:00:00) Welcome to Invest Like the Best (00:04:01) First question - Exploring public perceptions of Big Pharma (00:04:56) Providing an overview of the drug discovery process (00:07:22) Assessing the efficiency of the pharmaceutical industry (00:12:13) Anticipating the future direction of drug development (00:16:46) Categorizing different types of pharmaceutical drugs (00:21:19) Strategies to reduce the time from discovery to implementation (00:25:55) Gaining insights from cross-disciplinary research (00:31:13) The emerging role of AI in pharmaceuticals (00:34:32) Analyzing potential regulatory shifts in the industry (00:39:13) Discussing the importance of Randomized Controlled Trials (RCTs) (00:43:29) Examining the impact of blockbuster drugs (00:47:47) Deliberating on the complexities of drug pricing (00:54:09) Highlighting exciting developments and concerns in pharma (00:59:55) The kindest thing anyone has ever done for him

Invest Like the Best with Patrick O'Shaughnessy

enJanuary 30, 2024

artificial intelligence

pharmaceutical industry

drug development

gene therapy

regulatory processes

EP 155: AI's Edge in Pharma - Lowering Drug Failure Rates

Why do drugs fail at such a high rate? What can AI do about? We're asking an expert helping to lead the Pharma industry. Chris Gibson, Co-Founder and CEO at Recursion, joins us to discuss how GenAI is reshaping the Pharma industry and medical drugs.

Newsletter: Sign up for our free daily newsletter
More on this Episode: Episode Page
Join the discussion: Ask Chris and Jordan questions about AI and Pharma
Upcoming Episodes: Check out the upcoming Everyday AI Livestream lineup
Website: YourEverydayAI.com
Email The Show: info@youreverydayai.com
Connect with Jordan on LinkedIn

Timestamps:
[00:01:15] Daily AI news
[00:04:00] About Chris and Recursion
[00:06:30] Impact of AI and reducing drug failure
[00:12:15] Work being done in drug testing and AI
[00:16:45] LLMs being used in Pharma
[00:19:10] Challenges with data
[00:23:20] Future of medicine with AI
[00:26:20] Chris' final takeaway

Topics Covered in This Episode:
1. Why drugs fail at a high rate
2. Work being done in drug testing
3. AI's impact on drug research
4. How AI and drug testing work
5. Future of medicine with AI

Keywords:
AI, artificial intelligence, drug failure rates, Amazon, reInvent 2023 conference, Titan AI image generator, DeepMind, chemical materials, computer chips, solar panel, ChatGPT, Sam Altman, OpenAI, Microsoft, pharmaceutical industry, clinical trials, FDA approval process, data problem, technology tools, large language models, molecules, Trillions of relationships, public data set, Amazon Prime, healthcare, preventative medicine, AGI, mission-driven AI, Recursion, everyday AI show.

Everyday AI Podcast – An AI and ChatGPT Podcast

en-usNovember 30, 2023

What causes Alzheimer’s?

For decades, Alzheimer’s researchers have been stubbornly pursuing a single theory, but they’re starting to wonder: is this narrow focus the reason we still don’t have a cure? For more, go to http://vox.com/unexplainable It’s a great place to sign up for our newsletter, view show transcripts, and read more about the topics on our show. Also, email us! unexplainable@vox.com We read every email. Support Unexplainable by making a financial contribution to Vox! bit.ly/givepodcasts Learn more about your ad choices. Visit podcastchoices.com/adchoices

enSeptember 15, 2021

#164 - Amanda Smith, M.D.: Diagnosing, preventing, and treating Alzheimer’s disease, and what we can all learn from patients with dementia

Amanda Grant Smith is a geriatric psychiatrist with decades of experience treating patients with dementia and Alzheimer's disease. In this episode, Amanda shares how she developed a passion for geriatric psychiatry as a means to support dementia patients. She explains how to recognize, define, and diagnose dementia—a process that still remains somewhat elusive. They also talk about the significance of ApoE genotype and compare the various forms of dementia including differentiating between Alzheimer’s disease and Lewy body dementia. They discuss the current landscape of clinical trials, the drug pipeline, and talk about a very promising monoclonal antibody directed at amyloid beta that has the potential to be a disease-modifying drug. They conclude with a discussion about how to define “healthy aging” and reflect on how understanding dementia can shape one’s life philosophy.

We discuss:

How Amanda developed a passion for geriatric psychiatry [3:15];
Defining and diagnosing dementia and Alzheimer’s disease [13:30];
Medical tests for dementia and their relationship to clinical symptoms [22:45];
The pathology of dementia, and the role of the tau and beta-amyloid protein in Alzheimer’s disease [33:15];
The significance of ApoE genotype, and differentiating Alzheimer’s disease from Lewy body dementia [43:15];
The evolution of Alzheimer’s disease prevention, care, and medications over the last 20 years [52:45];
Psychiatric support for dementia patients (and caregivers) with depression and anxiety [1:02:45];
Drug pipeline, clinical trials, and major challenges to overcome [1:13:45];
Redefining Alzheimer’s disease and designing effective trials [1:23:00];
The promise of monoclonal antibody treatments for Alzheimer’s disease [1:34:15];
How we should measure outcomes in dementia trials and define “healthy aging” [1:42:30];
How understanding dementia can reshape our life philosophy [1:53:45]; and
More.

Learn more: https://peterattiamd.com/

Show notes page for this episode: https://peterattiamd.com/AmandaSmith

Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/

Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/

Connect with Peter on Facebook | Twitter | Instagram.

The Peter Attia Drive

enJune 07, 2021

#23 - Tom Dayspring, M.D., FACP, FNLA – Part IV of V: Statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain

In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part IV, Peter and Tom review the history and current use of drugs to prevent cardiovascular disease. They also discuss why some drugs appear to be more effective than others, an in-depth conversation about niacin, cholesterol and brain health, and the futility of using CKs (creatinine kinase) and liver function tests to identify adverse effects in statins, to name a few topics in this episode.

We discuss:

Bile acid sequestrants and statins [2:00];
Ezetimibe (Zetia) [15:00];
PCSK9 inhibitors [27:30];
Fibrates [41:00];
Fish oil, DHA, and EPA [1:01:00];
Niacin [1:05:15];
PCSK9 inhibitors [1:23:45];
Cholesterol, statins, and the brain [1:30:00];
Elevated creatine kinase (CK) and liver function tests (LFTs) on statins [1:50:30]; and
More.

Learn more at www.PeterAttiaMD.com

Connect with Peter on Facebook | Twitter | Instagram.

The Peter Attia Drive

enOctober 18, 2018

cholesterol management

personalized treatment

What drugs are astronauts on?

Make no mistake: Space is a very hostile environment. Astronauts in orbit suffer from conditions caused by the lack of gravity, small living quarters and other factors. So how do these astronauts cope? Tune in to learn more about the drugs used in space.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

See omnystudio.com/listener for privacy information.

Stuff To Blow Your Mind

enApril 22, 2010